Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor London, February 11, 2025: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is to develop a next-generation immuno-oncology drug which could [...]
Ellipses Pharma Launches Pioneering Clinical Trial Programme in Middle East London, December 23, 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the first large-scale Phase 1/2 oncology clinical study of its kind in the [...]
Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042 at ASH 2024 London, UK, 9th December 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from an ongoing Phase 1/2 clinical trial of EP0042, [...]
Ellipses’ next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2 clinical development Drug has successfully completed US Food and Drug Administration’s End of Phase 1 data review. Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the [...]
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours. Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that [...]
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]
Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]
Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]
Ellipses announces FDA clearance of IND application for EP0031 for patients with advanced RET-altered malignancies A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today [...]
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]
